Prostate Cancer-targeted PET Imaging Agent Market Size, Precision Diagnosis Applications and Global Growth Forecast 2026-2032 Global Leading Market Research Publisher QYResearch announces the release of its latest report “Prostate Cancer-targeted PET Imaging Agent - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Prostate Cancer-targeted PET Imaging Agent market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Prostate Cancer-targeted PET Imaging Agent was estimated to be worth US$ 1513 million in 2025 and is projected to reach US$ 2464 million by 2032, growing at a CAGR of 7.0% from 2026 to 2032. Driven by the rising global burden of prostate cancer, accelerated adoption of precision oncology, and continuous advances in molecular imaging technology, prostate cancer-targeted PET imaging agents are becoming essential diagnostic tools throughout the entire disease management cycle. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6981010/prostate-cancer-targeted-pet-imaging-agent Prostate Cancer-targeted PET Imaging Agent Market Overview and Technology Development Prostate cancer-targeted PET imaging agents are advanced radiopharmaceutical products administered intravenously to achieve highly accurate molecular imaging of prostate cancer lesions. Unlike traditional imaging technologies such as CT scans and bone imaging, these agents identify tumors through specific molecular targeting mechanisms, allowing clinicians to visualize cancer activity at the cellular level. In 2025, global production of prostate cancer-targeted PET imaging agents reached approximately 2.8812 million units, with an average selling price of US$525 per unit. The global annual production capacity was estimated at around 5 million units, while the gross margin was approximately 30.4%. The working principle of prostate cancer-targeted PET imaging agents relies on molecular probes that selectively bind to specific targets expressed on prostate cancer cells or within the tumor microenvironment. The most widely adopted clinical targets currently include prostate-specific membrane antigen (PSMA), while emerging targets such as fibroblast activation protein inhibitor (FAPI) are expanding application possibilities. After injection, radioactive signals generated by isotopes such as Gallium-68 (68Ga) or Fluorine-18 (18F) are captured by PET scanners, creating three-dimensional whole-body images. This enables highly sensitive detection of primary tumors, microscopic metastases, lymph node involvement, and recurrent lesions. Compared with conventional diagnostic methods, prostate cancer-targeted PET imaging agents provide improved sensitivity and specificity, making them increasingly valuable in initial staging, biochemical recurrence localization, treatment planning, and therapeutic response monitoring. Industrial Chain Analysis and Competitive Landscape The global prostate cancer-targeted PET imaging agent industry consists of upstream raw material suppliers, midstream radiopharmaceutical manufacturers, and downstream medical application providers. The upstream segment includes radioactive isotopes such as gallium-68 and fluorine-18, PSMA-targeting ligands based on small molecules, peptides, or antibodies, as well as chelators and advanced carrier materials. The quality, stability, and supply efficiency of these components directly influence production capacity and clinical availability. The midstream sector consists of specialized radiopharmaceutical companies responsible for molecular probe development, isotope labeling, pharmaceutical preparation, quality verification, and regulatory compliance. Due to the combination of nuclear technology, pharmaceutical manufacturing, and clinical validation requirements, the industry maintains relatively high technical barriers. The downstream application markets mainly include nuclear medicine and molecular imaging centers, precision oncology diagnostics, radiopharmaceutical distribution systems, and nuclear pharmacy networks. As cancer treatment strategies increasingly shift from standardized therapy toward individualized medicine, these applications are expected to expand further. Major participants in the prostate cancer-targeted PET imaging agent market include Lantheus, Telix Pharmaceuticals, Novartis, Blue Earth Diagnostics（Bracco）, Sinotau, DC PHARMA, Clarity Pharmaceuticals, Hengrui Pharma, CRAND PHARMACEUTICAL, Norroy Bioscience, HUAYI RADIOPHARMACEUTICALS, Yunhe Pharma, C Ray Therapeutics, Curium Holding France S.A.S., ABX advanced biochemical compounds GmbH, and Isotopia Molecular Imaging Ltd. Market Growth Drivers: Precision Oncology and Full-course Cancer Management The rapid development of precision oncology is the primary driver behind the expansion of the prostate cancer-targeted PET imaging agent market. As prostate cancer diagnosis and treatment become increasingly personalized, physicians require more accurate tools for identifying tumor location, evaluating disease progression, and selecting appropriate treatment strategies. The clinical application scope of these imaging agents has expanded significantly. Initially focused on detecting advanced metastatic prostate cancer, the technology is now increasingly used for: Early-stage disease staging; Localization of biochemical recurrence; Treatment decision support; Dynamic monitoring of therapeutic response. PSMA-targeted PET imaging agents currently represent the mainstream clinical solution due to their strong specificity for prostate cancer cells. However, new molecular imaging approaches such as FAPI-targeted agents are gaining attention because they may provide complementary diagnostic value for tumors with low PSMA expression or PSMA-negative characteristics. This multi-target development trend is creating a diversified application ecosystem, allowing physicians to select imaging approaches according to individual patient characteristics. Technical Innovation and Industry Challenges Continuous technological advancement is reshaping the prostate cancer-targeted PET imaging agent market. Improvements in radionuclide conjugation technology, automated synthesis equipment, and radiopharmaceutical distribution systems are enhancing production efficiency and clinical accessibility. Automated synthesis modules have reduced operational complexity and improved product consistency, while optimized logistics systems are helping healthcare providers overcome challenges caused by short isotope half-lives. However, several industry barriers remain. Radiopharmaceutical products require strict regulatory approval procedures, specialized manufacturing environments, and highly trained professionals. The short half-life characteristics of radioactive isotopes also create challenges in transportation, regional supply, and hospital scheduling. In addition, expanding global adoption requires further investment in nuclear medicine infrastructure and professional training. Emerging markets with limited access to advanced imaging facilities may require additional support before achieving widespread commercialization. Future Trends: From Imaging Diagnosis Toward Theranostic Integration The future development direction of prostate cancer-targeted PET imaging agents is moving toward higher precision, broader target diversity, and deeper integration with therapeutic applications. One major trend is the combination of diagnosis and treatment, known as theranostics. By using similar molecular targeting mechanisms for both imaging and therapy, healthcare providers can identify suitable patients and subsequently deliver targeted radioactive treatments. Another important trend is the development of individualized dosing strategies and next-generation molecular probes. Companies are increasingly focusing on improving tumor targeting efficiency, reducing background signals, and enhancing imaging accuracy. Market competition is also evolving. Instead of competing only through individual products, leading companies are building comprehensive capabilities covering molecular research, clinical cooperation, production reliability, and global service networks. Overall, the global prostate cancer-targeted PET imaging agent market is entering a period of sustained growth. Supported by precision medicine adoption, technological innovation, and increasing clinical demand, the industry is expected to advance toward greater standardization, accessibility, and integration with personalized cancer treatment systems. Market Segmentation The Prostate Cancer-targeted PET Imaging Agent market is segmented as below: Major Manufacturers: Lantheus Telix Pharmaceuticals Novartis Blue Earth Diagnostics（Bracco） Sinotau DC PHARMA Clarity Pharmaceuticals Hengrui Pharma CRAND PHARMACEUTICAL Norroy Bioscience HUAYI RADIOPHARMACEUTICALS Yunhe Pharma C Ray Therapeutics Curium Holding France S.A.S. ABX advanced biochemical compounds GmbH Isotopia Molecular Imaging Ltd. Segment by Type 68Ga 18F Segment by Application Nuclear Medicine and Molecular Imaging Precision Oncology Diagnostics Radiopharmaceuticals and Radiopharmaceuticals Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp